Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study. J of Skin [Internet]. 2019 Nov. 9 [cited 2025 Apr. 19];3:S41. Available from: https://skin.dermsquared.com/skin/article/view/768